Sam Brusco, Associate Editor10.10.23
Haemonetics has entered an acquisition deal with OpSens, a cardiology-focused company developing solutions based on optical technology. The deal has an equity value of about $253 million.
OpSens adds clinically validated optical technology for use mainly in interventional cardiology. The company’s SavvyWire is a sensor-guided, three-in-one guidewire for transcatheter aortic valve replacement (TAVR) procedures that provides pacing and pressure monitoring. Its OptoWire pressure guidewire measures fractional flow reserve (FFR) and diastolic pressure ratio (dPR) to assist with coronary artery disease diagnosis and treatment.
The company also makes a range of fiber optic sensors used in medical devices and other industrial applications.
Haemonetics’ president of Global Hospital Stewart Strong told the press, "With the acquisition of OpSens, we expand our leadership in interventional cardiology and strengthen our foundation for additional growth and diversification. By leveraging OpSens' proprietary optical sensor technology, our global commercial infrastructure, and our relationships with the top US hospitals performing TAVR and PCI procedures, we have a powerful opportunity to improve standards of care for more physicians and patients worldwide.
Haemonetics said combining the companies has the potential to make SavvyWire the leading guidewire for TAVR procedures. The company plans to further expand its Hospital business with OpSens’ technology.
Over the past year, Haemonetics has made other investments it said will complement the OpSens acquisition, including in VivaSure Medical, which developed PerQSeal percutaneous, large-bore vessel closure technology.
The company said it anticipates the acquisition of OpSens to close by the end of January 2024.
“We are excited to welcome OpSens' talented team and look forward to advancing our shared commitment to maximizing patient benefits and value for our customers," said Strong.
OpSens adds clinically validated optical technology for use mainly in interventional cardiology. The company’s SavvyWire is a sensor-guided, three-in-one guidewire for transcatheter aortic valve replacement (TAVR) procedures that provides pacing and pressure monitoring. Its OptoWire pressure guidewire measures fractional flow reserve (FFR) and diastolic pressure ratio (dPR) to assist with coronary artery disease diagnosis and treatment.
The company also makes a range of fiber optic sensors used in medical devices and other industrial applications.
Haemonetics’ president of Global Hospital Stewart Strong told the press, "With the acquisition of OpSens, we expand our leadership in interventional cardiology and strengthen our foundation for additional growth and diversification. By leveraging OpSens' proprietary optical sensor technology, our global commercial infrastructure, and our relationships with the top US hospitals performing TAVR and PCI procedures, we have a powerful opportunity to improve standards of care for more physicians and patients worldwide.
Haemonetics said combining the companies has the potential to make SavvyWire the leading guidewire for TAVR procedures. The company plans to further expand its Hospital business with OpSens’ technology.
Over the past year, Haemonetics has made other investments it said will complement the OpSens acquisition, including in VivaSure Medical, which developed PerQSeal percutaneous, large-bore vessel closure technology.
The company said it anticipates the acquisition of OpSens to close by the end of January 2024.
“We are excited to welcome OpSens' talented team and look forward to advancing our shared commitment to maximizing patient benefits and value for our customers," said Strong.